, and C-type NP 1-4 (CNP1-4)] in teleosts, but relative biological activity of the seven NPs has not been comprehensively examined using homologous peptides. In this study, we newly identified CNP3 and CNP4 in eels to use homologous peptides, but the CNP2 gene may have been silenced in this species. The CNP4 gene was expressed exclusively in the brain as CNP1, but the CNP3 gene, from which cardiac ANP, BNP, and VNP were generated by tandem duplication, was most abundantly expressed in the pituitary, suggesting its local action. All NPs induced hypotension dose dependently after intra-arterial injection with a potency order of ANP Ͼ VNP Ͼ BNP Ͼ CNP4 Ͼ CNP1 ϭ CNP3. The degree of hypotension was similar at the ventral and dorsal aorta, indicating similar actions on the branchial and systemic circulation. The hypotension induced by cardiac NPs was longer lasting than CNPs, probably because of the difference in preferential receptors. Among cardiac NPs, the hypotensive effect of VNP lasted much longer than those of ANP and BNP, even though VNP disappeared from the blood more quickly than ANP. To analyze the unique effect of VNP, we examined possible involvement of the autonomic nervous system using ANP, VNP, and CNP3. ␤-adrenergic blockade diminished hypotensive effects of all three NPs, but ␣-adrenergic and cholinergic blockade enhanced only the effect of VNP, suggesting a specific mechanism for the VNP action. The NP-induced tachycardia was diminished by all blockers examined. Furthermore, the cardiovascular action of VNP was not impaired by a blocker of NP receptor, HS-142-1. Taken together, the homologous NPs exhibit diverse cardiovascular actions in eels partially through the autonomic nervous system, and the unique VNP action may be mediated by a novel receptor that has not been identified in teleosts. natriuretic peptide family; hypotension; atropine; phentolamine; propranolol NATRIURETIC PEPTIDES (NPS) form a family of peptides consisting of atrial, brain, ventricular, and C-type natriuretic peptide [atrial NP (ANP), brain NP (BNP), ventriclar NP (VNP), and C-type NP 1-4 (CNP1-4)]. Among the NPs, ANP was first identified as a potent diuretic/natriuretic and hypotensive factor from the rat atrium (5). Subsequently, BNP was discovered from the porcine brain followed by isolation of CNP from the brain of several species, including fish (32) and VNP from the eel cardiac ventricle (48). For more than a decade after the discovery, it had been thought that ANP/BNP/CNP and ANP/ VNP/CNP form a NP family in mammals and teleosts, respectively (50, 55). However, BNP and four distinct CNPs (CNP1 to CNP4) were identified in several teleost species (17, 20, 29) . Molecular evolutional studies showed that the ancestral molecule of the NP family is CNP4, from which other CNPs are generated (30). Cardiac NPs (ANP, BNP, and VNP) are generated from CNP3 by tandem duplication on the same chromosome (17). The seven NPs appear to have existed before the divergence of ray-finned fish and lobe-finned fish, and some of the NP genes have been lost during evolution in each lineage (54). Interestingly, BNP exists in all vertebrate species thus far examined except for chondrochthyeans and cyclostomes, while ANP is lost in birds, diapsid reptiles, and some teleosts (20, 57, 58) , and VNP exists only in some primitive ray-finned fishes such as eel, trout, sturgeon, and bichir (20, 58). Ray-finned fishes still retain the most diversified NPs in vertebrates, as seven NPs have been identified in some species.
covery, it had been thought that ANP/BNP/CNP and ANP/ VNP/CNP form a NP family in mammals and teleosts, respectively (50, 55) . However, BNP and four distinct CNPs (CNP1 to CNP4) were identified in several teleost species (17, 20, 29) . Molecular evolutional studies showed that the ancestral molecule of the NP family is CNP4, from which other CNPs are generated (30) . Cardiac NPs (ANP, BNP, and VNP) are generated from CNP3 by tandem duplication on the same chromosome (17) . The seven NPs appear to have existed before the divergence of ray-finned fish and lobe-finned fish, and some of the NP genes have been lost during evolution in each lineage (54) . Interestingly, BNP exists in all vertebrate species thus far examined except for chondrochthyeans and cyclostomes, while ANP is lost in birds, diapsid reptiles, and some teleosts (20, 57, 58) , and VNP exists only in some primitive ray-finned fishes such as eel, trout, sturgeon, and bichir (20, 58) . Ray-finned fishes still retain the most diversified NPs in vertebrates, as seven NPs have been identified in some species.
NPs play important roles in body fluid and cardiovascular homeostasis in vertebrates, which are achieved by their effects, such as vasodilatation, natriuresis/diuresis, and regulation of other hormone release (9, 32, 50, 51, 55) . In particular, the hypotension induced by vasodilatation is commonly observed in all vertebrate species thus far examined. In fishes, intravascular injection of ANP, or heart extracts, depressed aortic pressure in several fish species, and perfusion pressure in the gill and trunk preparation of the trout (9, 32) . These effects were attributed to a direct vasorelaxant effect on vascular smooth muscle (9, 32) . VNP and CNP1 are potent vasodepressors and vasodilators in fishes in vivo and in vitro (18, 32, 47) . In the trout, ANP and VNP initially induced hypertension, which is ascribed to the activation of the neural ␣-adrenergic system (34, 39) . BNP is a new clinical target for prognosis of heart failure in the human (1), but cardiovascular effects by BNP have not been examined to date in fishes. In eels, cardiac NPs (ANP, BNP, VNP) are released into the circulation triggered primarily by increased osmotic load to the heart (26) , but in the trout, by myocardial stretch caused by increased preload on the heart as in mammals (4) . Johnson and Olson (21, 22) suggested that NP-induced hypotension protects the heart from the increased preload and the subsequent afterload. CNP1 is produced mainly in the brain, but it seems to circulate in the eel blood at significant concentrations (50) . However, the role of circulating CNP1 in cardiovascular regulation is still unclear in teleosts.
Four NP receptors, NPR-A, B, C, and D, have been identified in the eel and classified in two subtypes based on differences in the intracellular domain (16) . NPR-A and -B are guanylyl cyclase (GC)-coupled receptors and exhibit the NPs' bioactivity through cGMP. NPR-A is a receptor for cardiac NPs with a potency order of ANP ϭ VNP ϾϾ CNP1 in eels (27) . NPR-B is a receptor for CNP1 with a potency order of CNP1 ϾϾ VNP Ͼ ANP (28) . Medaka BNP and CNP3 induced cGMP production in medaka homologs of NPR-A but not of NPR-B, while medaka CNP1, 2, and 4, but not CNP3, induced cGMP production in medaka homolog of NPR-B (17, 20) . NPR-C lacks the intracellular GC catalytic domain and has high affinity to all NPs, and thus it is suggested to be a clearance receptor to regulate plasma NP concentration (16) . NPR-C and additional GC-deficient receptor, NPR-D, have been identified in eels (26, 46) . HS-142-1, an antagonist of GC-coupled NP receptors (35) , inhibits the binding of NPs to NPR-A, NPR-B, and NPR-D (26, 45) . Compared with diversified NP ligands, only two GC-coupled receptors have been identified in teleosts.
Despite the accumulated evidence for the role of ANP in cardiovascular regulation, little is known about the cardiovascular action of the other NPs in teleost fishes, in which diversified NPs exist. In particular, three cardiac NPs and multiple CNPs exist only in the trout and eel among teleosts species, but comparative studies using homologous peptides, have not been done in these species. The aim of this study is to compare the cardiovascular effects of multiple NPs using conscious eels to obtain some clues for understanding the significance of diversified NPs in teleosts. The effects were monitored at both ventral and dorsal aorta to compare the relative effects on gill and systemic circulation because it was shown that NPs decreased gill resistance but increased systemic resistance in the trout (40) . As eel CNP2, CNP3, and CNP4 cDNAs had not yet been identified, we initially attempted to isolate these cDNAs for comparison of all NPs using homologous peptides. In addition, we performed molecular phylogenetic analyses to confirm the NP species and examined their tissue distribution of the gene transcripts. Then, the putative mature peptides were chemically synthesized, and all NPs were injected into the dorsal aorta of conscious eels to compare their cardiovascular effects. We also attempted to make some analyses for the involvement of autonomic nervous system, plasma clearance, and receptor blockade because distinct difference was detected in the NP effects.
MATERIALS AND METHODS

Animals
Cultured eels, Anguilla japonica, were purchased from a local dealer. They were acclimated in the freshwater tank without feeding for more than a week before use. Water in the tank was filtrated, aerated, and maintained at 18°C. All animal experiments described in this paper were approved by the Animal Experiment Committee of the University of Tokyo and performed in accordance with the Manual for Animal Experiments prepared by the committee.
RNA Extraction
After anesthesia in 0.1% (w/v) tricaine methanesulfonate (Sigma, St. Louis, MO), the brain, pituitary, gill, heart, interrenal, head kidney, kidney, esophagus, stomach, intestine, liver, pancreas, spleen, mesentery, red body, skin, and skeletal muscle were isolated from eels and immediately frozen in liquid nitrogen. Total RNA was extracted using ISOGEN (Nippongene, Toyama, Japan) for subsequent experiments.
cDNA Cloning of Eel CNP2, CNP3, and CNP4 Double-stranded cDNA pool was prepared from 1.0 g of total RNA using a SMART cDNA library construction kit (Clontech Labratories, Palo Alto, CA). The 5= region of the cDNAs was amplified by 5= rapid amplification of cDNA ends (RACE) using the 5= PCR primer in the kit and degenerate primers designed according to the known nucleotide sequences of each CNP species in teleosts (Table 1) . Gene-specific primers were designed based on the partial sequences, and then the 3= region of the cDNAs was amplified by the 3= RACE method using CDS III/3= primer in the kit and gene-specific primers (Table 1 ). Finally, cDNAs that encompassed the whole coding region of each CNP were amplified using gene-specific primers designed based on the partial sequences determined by the RACE method. Amplified products were subcloned into pT7blue vector (Novagen, Madison, WI) and then sequenced by a 3130 DNA sequencer (Applied Biosystems, Foster City, CA).
Phylogenetic Analyses of Eel NPs
Putative amino acid sequences of eel CNP precursors were aligned with those of other species using the ClustalX version 1.83 (ftp:// ftp-igbmc.u-strasbg.fr/pub/ClustalX/), which was followed by manual adjustments of inconsistencies. A phylogenetic tree was constructed by Bayesian method, using MrBayes version 3.1.2 software (http:// mrbayes.csit.fsu.edu/).
Tissue Distribution of NP mRNAs
Tissue distribution of each NP transcript was examined by RT-PCR. Single-strand cDNAs of various tissues were prepared from 1.0 g of total RNA using Superscript First-Strand Synthesis System (Invitrogen, Calsbad, CA), and PCR was performed using Ex Taq DNA polymerase (TaKaRa, Tokyo, Japan). ␤-actin cDNA (accession no. AB074846) was used for an internal standard. The PCR was performed as follows: initial denaturation at 94°C for 3 min was followed by 25 cycles for ␤-actin, 27 cycles for CNP3, 30 cycles for ANP, BNP, VNP, CNP1, and CNP4 of denaturation (94°C, 30 s), 
annealing (60°C, 30 s) and extension (72°C, 45 s). The amplified DNA fragments were electrophoresed on a 1.2% agarose gel and detected by ethidium bromide staining.
Peptide Synthesis
Predicted mature peptides of eel ANP, BNP, VNP, CNP1, CNP4, and medaka CNP3 were chemically synthesized by the Peptide Institute (Osaka, Japan) and used in physiological studies. Medaka CNP3 was used in the physiological study because only a single amino acid is different between eel and medaka CNP3 at the Nterminal region, which has little influence on the biological activity (47, 60) . These peptides were synthesized by a peptide synthesizer 430A (Applied Biosystems) with p-methyl-benzhydrylamine resin as a solid support. The correct sequence was confirmed by mass spectrophotometrical analysis, amino acid analysis, and reverse-phase HPLC. Each peptide was dissolved in distilled water at a concentration of 10 Ϫ4 M, aliquoted, and kept at Ϫ20°C until use. The stock solution was diluted with 0.9% NaCl containing 0.01% Triton-100 for injection.
Physiological Studies
Cardiovascular action of NPs. To examine the cardiovascular effects of NPs, nine eels (201.7 Ϯ 5.7 g) were used in the experiments. Eels were anesthetized in 0.1% (wt/vol) tricaine methanesulfonate (Sigma) for 15 min and placed on an operation board for surgery. The ventral and dorsal aortae were cannulated with polyethylene tubes (0.8 mm OD) for bolus injection of hormones and measurement of blood pressure, as described previously (47) . After surgery, eels were placed in a plastic trough through which aerated water circulated at 18°C. On the next day of surgery, the tubes were connected via a three-way stopcock to disposable pressure transducers (DX-300, NIHON KODEN, Tokyo, Japan) for continuous monitoring of blood pressure at the ventral aorta (PVA) and dorsal aorta (PDA). The signal was amplified by a carrier amplifier (7903, NEC San-ei, Tokyo, Japan) and recorded by water balance monitoring system MTS00658 (Medical Try System, Tokyo, Japan). Eels were injected with 0.01, 0.03, and 0.1 nmol/kg of ANP, BNP, and VNP, or with 0.03, 0.1, and 0.3 nmol/kg of CNP1, CNP3, and CNP4 in 0.05 ml of 0.9% NaCl containing 0.01% Triron-100 into the dorsal aorta in random order of doses. To avoid excess repetitive injection, each eel was injected with four different NPs. Each injection was immediately followed by an injection of 0.05 ml of saline to flush the dead volume of tubes. Injection intervals were more than 1 h apart to ensure reproducible response.
Effect of blockers. To examine the involvement of the autonomic nervous system in the NP effects, eight eels (201.9 Ϯ 4.3 g) were pretreated with phentolamine (25 g/eel), propranolol (25 g/eel), or atropine (5 g/eel) (Sigma), and ANP, VNP, or CNP3 were injected after 15 min at a dose of 0.1 nmol/kg (ANP and VNP) and 0.3 nmol/kg (CNP3) with intervals of more than 2 h. We confirmed that these doses of blockers are sufficient to attenuate the cardiovascular effects of ACh, norepinephrine, and isoproterenol (data not shown). In addition, HS-142-1, an antagonist for NPR-A and NPR-B, was injected at a dose of 3 mg/eel, and ANP or VNP was injected after 10 min at a dose of 0.1 nmol/kg. HS-142-1 was kindly provided by Kyowa Hakko Kogyo, (Tokyo, Japan).
Plasma clearance. The ventral aorta was cannulated with the polyethylene tube in eels. After injection of 0.1 nmol/kg of ANP or VNP, blood (0.15 ml) was sampled via the cannula just before and 0.5, 2, 5, 10, 15, 30, and 60 min after the injection. Plasma concentration of ANP and VNP was measured by homologous radioimmunoassay (25) . The time course of the plasma concentration was fitted to a double exponential curve for calculation of the plasma concentration and volume of distribution (Vss), which means the ease of distribution to the extravascular space. The metabolic clearance rate (MCR), which was calculated by the numerical method of Norland and Fortier (37) , means the rate of elimination of ANP and VNP out of body.
Statistical Analyses
Relative changes in PVA and PDA were compared by nonparametric Mann-Whitney U-test. Changes in PVA and heart rate after each treatment were compared with controls at each dose by the Dunnet multiple-comparison test. Changes in PVA and heart rate, and time for maximum change, were compared among treatments at each dose by Tukey multiple-comparison test. Kinetics parameters were compared between ANP and VNP by Student's t-test or Aspin-Welch test. Significance was determined at P Ͻ 0.05. All results were expressed as means Ϯ SE. 
RESULTS
cDNA Cloning of Eel NPs
Two cDNAs encoding eel NPs were amplified from a cDNA pool of the eel brain. These genes were identified as orthologs of CNP3 and CNP4 on the basis of the homology of the putative mature sequence of the cloned eel NPs with those of other bony fishes ( Fig. 1 ) and on the molecular phylogenetic analysis of the precursor protein (Fig. 2) . Eel CNP3 and CNP4 consisted of 128 and 120 amino acid residues, respectively. The putative mature sequence at the C-terminus had structural characteristics of CNP, such as an inferred intramolecular ring formed by two Cys residues and the absence of C-terminal tail sequences. As identification of CNP2 cDNA was not successful, we attempted to confirm the existence of CNP2 gene in the eel genome. CNP2-like sequence was isolated from the genomic DNA, but the sequence was not detected in the cDNAs from various eel tissues using specific primers. Thus the CNP2-like sequence is not expressed as mRNA. The eel CNP3 and CNP4 cDNAs and two CNP2-like nucleotide sequences were registered to the DDBJ/EMBL/GenBank nucleotide sequence databases (Accession nos. AB 513621, 513623, 513703, 513704).
Tissue Distribution of NP mRNAs
Expression of the NP genes in each tissue was detected by RT-PCR (Fig. 3) . The ANP and VNP mRNAs were exclusively detected in the heart, and the CNP1 and CNP4 mRNAs in the brain. The BNP gene was strongly expressed in the heart and weakly in the pituitary. The CNP3 gene was most abundantly expressed in the pituitary followed by the brain and intestine, and weakly in the heart and pancreas.
Cardiovascular Effects of NPs Injected Peripherally
Mean PVA and PDA, measured before injection, were 28.6 Ϯ 1.6 and 18.6 Ϯ 1.0 mmHg (n ϭ 9), respectively. After injection of NPs, both PVA and PDA were depressed to a similar extent (Fig. 4) . The depressor effects of all NPs were similar in efficacy (Ϫ6.1 to Ϫ7.7 mmHg) but different in potency; the maximum depression occurred at a dose of 0.03 nmol/kg of ANP, 0.1 nmol/kg of BNP and VNP, and 0.3 nmol/kg of CNPs (Fig. 5A) . The hypotensive effect of NPs was dose dependent within the range examined. Significant hypotension was observed at doses higher than 0.01 nmol/kg for ANP and VNP, 0.03 nmol/kg for BNP and CNP4, and 0.1 nmol/kg for CNP1 and CNP3 compared with that of saline (Fig. 5A) . Comparing the time course, cardiac NPs depressed PVA for Ͼ30 min after injections, whereas depressor effect of CNPs lasted Ͻ30 min after injection ( Table 2 ). The maximum decrease was attained Ͼ10 min after injection of VNP, but Ͻ10 min after injection of other NPs (Table 3 ). The degree of hypotension is similar between PVA and PDA at all doses (Fig. 5B) . Heart rate increased in parallel with the hypotension after any NP injections, although the increases were statistically significant only at a dose of 0.1 nmol/kg of ANP and BNP (Figs. 4 and 5A) .
Effects of Antagosists on NP-Induced Hypotension
As shown in Fig. 4 and Table 2 , the time course of the hypotensive effect differed among NPs. To elucidate the cause of difference, ANP, VNP, and CNP3 (a possible circulating CNP) were injected into the eel pretreated with the antagonists of autonomic nerve system. Atropine profoundly increased heart rate for more than 15 min, but the increase in PVA was not significant (Fig. 6A) . Phentolamine depressed PVA by Ϫ4.0 Ϯ 0.4 mmHg for 15 min without significant change in heart rate (Fig. 6A) . Propranolol decreased heart rate without effect on PVA (Fig. 6A ). It appears that the cholinergic and ␤-adrenergic systems are principally involved in cardiac regulation, whereas the ␣-adrenergic system is involved in the maintenance of blood pressure in eels.
Hypotension induced by the 3 NPs was diminished by propranolol (Fig. 6, B-D) . Interestingly, the VNP-induced hypotension was enhanced by atropine and phentolamine but not ANP and CNP3-induced hypotension. In particular, VNP decreased PVA more quickly after atropine and phentolamine treatment than in controls (Fig. 6C) . The effects of blockers were statistically significant compared with controls (P Ͻ 0.001 by two-way ANOVA in both cases). All three antagonists inhibited tachycardia induced by the three NPs (Fig. 6E) . After pretreatment with HS-142-1, ANP-induced hypotension tended to decrease (from Ϫ5.8 Ϯ 2.2 to Ϫ3.0 Ϯ 0.8 mmHg, n ϭ 3), whereas VNP-induced hypotension remained unchanged after HS-142-1 (from Ϫ5.2 Ϯ 0.9 to Ϫ5.7 Ϯ 0.7 mmHg, n ϭ 3). Because of the limited supply of HS-142-1, we could not increase the number of animals.
Kinetics Analysis of Plasma ANP and VNP
Because the VNP effect lasted much longer than that of ANP, we compared plasma clearance rates of the two peptides in eels. Plasma concentrations of endogenous ANP and VNP were 60.5 Ϯ 14.7 and 62.4 Ϯ 8.0 fmol/ml, respectively. The time-course changes in plasma ANP and VNP concentrations were significantly different after the injection (P Ͻ 0.05 by two-way ANOVA) (Fig. 7) . ANP and VNP disappeared from plasma with greatest fitting to a double exponential curve of Y ϭ 1,524.3e Ϫ2.0t ϩ 951.2e Ϫ0.1t ϩ 40.3 and Y ϭ 5,527.2e Ϫ2.0t ϩ 274.7e Ϫ0.06t ϩ 27.2, respectively, where Y and t represent the plasma concentration and the time after injection, respectively. The Vss was estimated to be 13.1 ml for ANP and 30.0 ml for VNP ( Table 4 ). The MCR of VNP (2.7 ml/min) was higher than that of ANP (1.7 ml/min). There were significant differences in the Vss and MCR between ANP and VNP. Assuming that the plasma concentration just after injection of 0.1 nmol/kg is 5,586.6 fmol/ml calculated from the plasma volume of 17.9 ml/kg in eels (49) , the plasma concentration of ANP and VNP decreased to one-seventh and one-fifteenth the initial value within 2 min after injection, respectively. Injected VNP was cleared from the circulation faster than ANP, within a few minutes after injection.
DISCUSSION
Teleosts have the most diversified NPs in vertebrates, but comparative studies using homologous hormones have not been performed, including cardiovascular actions in this fish group, but not in the trout (22) , despite intensive studies using heterologous NPs in other teleost species (32) . We initially attempted to identify CNP2, CNP3, and CNP4, which have not been identified in eels, but isolation of CNP2 mRNA was not successful in spite of isolation of partial CNP2-like sequence from genomic DNA. CNP2 has been identified only in a few teleost species, such as trout, pufferfish, and medaka (Oryzias latipes) (Fig. 1) . However, the CNP2 gene is mutated at the region within the coding sequence in another medaka species (O. marmoratus) (H. Miyanishi and Y. Takei, unpublished data). The CNP2 gene was neither identifiable in the bichir (59) . In addition, CNP2 has high sequence identity with CNP1 in the intramolecular ring (Fig. 1) , suggesting the duplication of one gene from the other (19) . Therefore, it seems that the CNP2 gene is changeable during evolution. Thus, we concluded that six NPs, excluding CNP2, exist in eels. This is the first report that compares the cardiovascular actions of diversified NPs in teleosts using homologous peptides.
All NPs, especially cardiac NPs, induced profound hypotension when injected peripherally into eels. Plasma concentrations of ANP and VNP are maintained at ϳ2.0ϫ10 Ϫ11 to 7.0ϫ10 Ϫ11 M in eels, and they increase to three-fold after environmental salinity changes (23, 24) . Thus, plasma concentrations of endogenous ANP and VNP increase up to 21.0ϫ10 Ϫ11 M in a physiological state. Judging from the mean plasma concentrations just after the injection of 0.1 nmol/kg of ANP and VNP (Fig. 7) , the injection of 0.01 nmol/kg may elevate the plasma concentrations to 23.0ϫ10 Ϫ11 M, which falls within the physiological range. Both ANP and VNP Fig. 5 . A: dose-dependent effects of NPs on hypotension and tachycardia in eels (n ϭ 6). In hypotensive effects, significant differences (P Ͻ 0.05) were detected at doses higher than 0.01 nmol/kg (ANP and VNP), 0.03 nmol/kg (BNP and CNP4) and 0.1 nmol/kg (CNP1 and CNP3) compared with controls by Dunnet's multiple-comparison test. In tachycardiac effects, significant differences (P Ͻ 0.05) were detected at a dose of 0.1 nmol/kg (ANP and BNP) compared with controls by Dunnet multiple-comparison test. B: relative decreases in blood pressure at the PVA and PDA aorta at 0.1 nmol/kg (ANP, BNP, and VNP) or 0.3 nmol/kg (CNPs) (n ϭ 6). Values are normalized as percent decreases from the value before injection. Differences between PVA and PDA were not significant by Mann Whitney's U-test.
significantly depressed PVA at doses higher than 0.01 nmol/kg compared with vehicle injection, indicating that ANP and VNP physiologically contribute to the regulation of blood pressure in an endocrine fashion. BNP and CNP3 may also be released from the heart and pituitary to the circulation although plasma concentrations of these NPs have not been measured in eels. However, as BNP and CNP3 were only slightly hypotensive at 0.01 nmol/kg, ANP and VNP may be major cardiovascular regulators. In this study, CNP mRNAs were abundant in the brain or pituitary, which coincides with the report that tilapia CNP1 promotes the release of growth hormone from cultured tilapia pituitary cells (13) . It is interesting to examine whether CNP3 has effects on the pituitary hormone secretion.
Cardiac NPs induced hypotension for a longer period than CNPs (Table 3) , which can be attributed to the difference in their preferential receptors (NPR-A for cardiac NPs and NPR-B for CNPs). Among cardiac NPs, the hypotension continues much longer after VNP than after ANP (Fig. 4, Table 2 ). To analyze the difference, plasma concentrations of ANP and VNP were compared. Both ANP and VNP disappeared from the plasma with biphasic manner as fitted by a double exponential curve. In the first phase that was observed until 2 min after the injection, VNP disappeared from the plasma much more quickly than ANP, as indicated by higher Vss and MCR of VNP. The disappearance will be attributed to some factors, such as diffusion to the extravascular space, binding to the clearance receptor (NPR-C and NPR-D), metabolism, degradation, and elimination. Although it is unclear which factor causes the difference in kinetics between ANP and VNP, it is likely that the rapid disappearance of VNP in blood is related to the lower potency. These results indicate that the difference of the hypotensive effects is, in part, attributed to the kinetics of NPs, although it is unreasonable to explain the longerlasting effect of VNP.
To analyze the difference further, involvement of the adrenergic and cholinergic systems in NP-induced hypotension were examined. Hypotension and tachycardia induced by NPs were weakened by the pretreatment with propranolol, blockers of ␤-adenoceptor (Fig. 6, B-E) . The activation of ␤-adrenergic system by isoproterenol induced reduction of blood pressure in this study (data not shown). Adrenergic innervations to branchial afferent and efferent filament vessels are involved in the vasodilatation through the activation of ␤-adenoceptor in teleosts (8) . Catecholamines decreased branchial resistance in eels, Anguilla Anguilla, which is attenuated by the pretreatment with propranolol (11) . These findings strongly suggest that neural and/or hormonal catecholamines mediate, in part, the NP-induced hypotension through ␤-adenoceptor. Actually, NPs are branchial vasodilators (41) , which is, in part, due to the ␤-adrenergic activation in trout arteries (38) . Judging from the fact that injection of eel ANP and VNP did not increase plasma catecholamines in the eel, Anguilla rostrata (34), NPs would activate neural ␤-adrenergic system to induce branchial vasodilatation, which contributes to NP-induced hypotension. Adrenergic innervations to the heart are known to be involved in cardio-stimulation through ␤-adenoceptor in teleosts (6, 12) . NP-induced tachycardia may be induced through the activation of ␤-adenoceptor although reflexogenic tachycardia may also be caused by abrupt hypotension.
In eels treated with atropine, VNP-induced hypotension was significantly enhanced compared with controls (Fig. 6C) , suggesting an involvement of cholinergic system through the muscarinic receptor. In teleosts, cholinergic innervations contribute to the increasing of branchial resistance, which is attenuated by the pretreatment with atropine (8), but it remains uncertain whether cholinergic nerves innervate systemic circulation and directly regulate blood pressure (42, 53) . Intraarterial injection of ACh increased arterial pressure in this study (data not shown) and ACh causes vasoconstriction in the eel ventral and dorsal aorta (7, 20, 43) , although it is unclear whether the constriction is induced through the muscarinic receptor or not. Therefore, it is possible that VNP activates cholinergic system and exerts the pressor effect in eels. Phentolamine enhanced VNP-induced hypotension as did atropine, which suggests that VNP also activates the ␣-adrenergic system in eels. Homologous VNP induced transient hypertension, which is ascribed to the activation of the neural ␣-adrenergic system in the trout and did not increase plasma catecholamines in the eel, Anguilla rostrata (34) . In addition, catecholamines increased PVA, PDA, and systemic resistance through the ␣-adrenergic system (10, 11, 15) . In VNP-induced hypotension, it is likely that the dominant depressor effect induced by the direct vasodilatation apparently masked the pressor action mediated through the activation of cholinergic and ␣-adrenergic system. The masked pressor effects may delay the peak time of VNP-induced hypotension (Table 2) , because the effects of atropine and phentolamine were profound around 5 min after injection of VNP (Fig. 6C) . Interestingly, atropine and phentolamine did not alter the effect of ANP and CNP3 (Fig. 6, B and D) . This indicates that VNP depressed blood pressure through a different mechanism from ANP. Values are expressed as means Ϯ SE; n ϭ 6. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; VNP, ventricular natriuretic peptide; CNP, C-type natriuretic peptide. The difference between preinjection and 30 min after injection was compared by paired t-test (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001). Values are expressed as means Ϯ SE; n ϭ 6. The differences among NPs were compared by Tukey multiple-comparison test (*P Ͻ 0.05 and **P Ͻ 0.01) to VNP.
HS-142-1, a blocker of guanylyl-cyclase coupled NP receptor, did not inhibit VNP-induced hypotension, although it apparently inhibited ANP-induced hypotension. We could not increase the sample number because HS-142-1 is no longer available. However, it seems that an unknown receptor that has high affinity to VNP over ANP may be present in the eel. As HS-142-1 acts not only on mammalian NPR-A and NPR-B, but also on shark NPR-B (14), it probably acts on eel NPR-A and NPR-B. Thus, we suggest a possibility that VNP depresses blood pressure through an unknown receptor that is not blocked by HS-142-1. In addition, CNP3 depressed blood pressure as efficaciously as other CNPs in eels despite the fact that CNP3 has low affinity to NPR-A and NPR-B in medaka (17) . If CNP3 has low affinity to NPR-A and NPR-B in eels as well, CNP3 may act through a receptor other than NPR-A and NPR-B. Judging from the diversified NPs in teleosts, it is likely Fig. 6 . A: changes in blood pressure at ventral aorta and heart rate after injection of antagonists of adrenoceptor and cholinergic receptors (n ϭ 8). The values are represented by those at 15 min after injection, because natriuretic peptides were injected at that time. B-D: PVA after injection of ANP (B), VNP (C), and CNP3 (D) (0.1 nmol/kg) in eels pretreated with saline, atropine, phentolamine, and propranolol. E: heart rate after injection of ANP, VNP, and CNP3 (0.1 nmol/kg) in eels pretreated with saline, atropine, phentolamine, and propranolol. A-F: difference between each antagonist and saline treatment was compared using two-way ANOVA followed by Dunnet's multiple-comparison test (*P Ͻ 0.05, **P Ͻ 0.01 and ***P Ͻ 0.001).
that multiple NP receptors other than NPR-A and NPR-B exist for the full performance of the ligands.
Atropine and phentolamine inhibited tachycardia induced by all NPs examined. Atropine also inhibited rat ANP-induced tachycardia in the Atlantic cod (2) . However, these results are inconsistent with the cardio-inhibitory effect of cholinergic system through the muscarinic receptor in eels and other teloests (3, 54) . Atropine alone induced tachycardia, which lasted for Ͼ15 min after the injection, due to nullification of cardiac vagal tone. Likewise, phentolamine induced tachycardia, probably attributed to cardio-inhibitory effect through the ␣-adenoceptor, as observed in the trout (31) . NPs may be hard to induce further tachycardia after tachycardia induced by atropine and phentolamine. Alternatively, NPs may increase heart rate, in part, by nullification of the cardio-inhibitory effects through the muscarinic receptor or ␣-adenoceptor. Tsukada et al. (56) suggested that circulating ANP acts on the area postrema (AP) in the hindbrain to inhibit drinking in eels. They found that the AP is an exclusive site of action of circulating ANP in the eel brain because of a loose blood-brain barrier and expression of NPR-A. The AP is important for the regulation of blood pressure in vertebrates (33) . Action of circulating NPs on the AP may be one of the pathways for the activation of the autonomic nervous system in NP-induced hypotension and tachycardia. Taken together, NPs modulate blood pressure and heart rate through the activation of the autonomic nervous system in addition to the direct vasodilatation of vascular smooth muscle in eels.
Recently, we found that homologous adrenomedullin 2 and 5 (AM2 and AM5) are less potent and more efficacious vasodepressor hormones compared with ANP in eels (36) . In contrast to ANP that is expressed mainly in the heart, AM2 and AM5 are ubiquitously expressed in various tissues and locally regulate blood flow in an autocrine or paracrine fashion. From this aspect, it is reasonable that these AMs depress PDA more profoundly than PVA at concentrations as high as 1.0 nmol/kg. On the other hand, the cardiac NPs are released from the heart into the circulation and depressed PVA and PDA to the same extent at lower doses (Fig. 5B) . It has been suggested that ANP depresses arterial blood pressure through a decrease in venous return and cardiac output rather than through a decrease in systemic resistance, and this contributes to the protection of the heart from volume overload in the trout (40) and eels (44) . As excess decreases in venous return or cardiac output deteriorates cardiovascular and respiratory homeostasis, cardiac NPs may not be able to induce hypotension as severe as induced by AM2 and AM5. The differences of site of action (gill circulation vs. systemic circulation) and efficacy between NPs and AMs may be related to the difference in their physiological roles.
In summary, all NPs identified in eels consistently depress blood pressure when injected into the circulation. The cardiovascular actions of NPs are diverse due to different kinetics in the blood and different degree of activation of autonomic nervous system. We suggest the presence of novel receptors for diversified ligands, which also account for the diversified actions. In teleosts, it seems that diversified vasodepressor hormones and their receptors are involved in the cardiovascular regulation to ensure the maintenance of low arterial pressure of this aquatic animals through the various mechanisms (52) , but the regulatory system differs greatly among species because of large diversification of physiology in teleosts (21).
Perspectives and Significance
As mentioned above, it seems that the vasodepressor hormones play more important roles than the vasopressor hormones for the maintenance of low arterial pressure in aquatic fishes as exemplified by their high potency and the multiplicity in fishes compared with mammals (52) . This idea will be supported not only by the diversification of hormones but also by the diversification of the mechanism of action. This study suggested the presence of unknown NP receptors in line with diversified NP ligands, and we have recently isolated partial NPR-like sequences other than NPR-A and NPR-B in eel tissues (see Supplemental Figure 1 in the online version of this article). Identification of novel NP receptors will offer insight into a deeper understanding of the physiological functions of diversified NPs and the significance of diversification of vasodepressor hormones, such as NP and AM. We initially expected that BNP would be more potent than ANP and VNP because BNP is a common cardiac NP throughout teleosts. For example, BNP is the only cardiac hormone in some teleosts such as medaka (19) . However, this was not the case in eels as shown in this study. It will be interesting to examine whether the vasodepressor effect of BNP is highly potent in medaka that has lost ANP and VNP and whether their function is replaced by CNPs or other vasodepressor hormones. Teleosts are best suited to understand the significance of diversification of NPs. Values were means Ϯ SE; n ϭ 6. Vss, volume distribution; MCR, metabolic clearance rate. The difference between ANP and VNP was compared by Student t-test or Aspin-Welch test (**P Ͻ 0.001). Fig. 7 . Time course of change in plasma concentration after injection of ANP and VNP (n ϭ 6). The plasma concentration of VNP was compared with that of ANP using two-way ANOVA followed by Student's t-test or Aspin-Welch test (*P Ͻ 0.01, **P Ͻ 0.001).
